Source: European Medicines Agency (EU) Revision Year: 2023 Publisher: Otsuka Pharmaceutical Netherlands B.V., Herikerbergweg 292, 1101 CT Amsterdam, Netherlands
Lupkynis 7.9 mg soft capsules.
Pharmaceutical Form |
---|
Soft capsule (capsule). Pink/orange oval soft capsules measuring approximately 13 mm × 6 mm. |
Each soft capsule contains 7.9 mg of voclosporin.
Excipients with known effect: Each soft capsule contains 21.6 mg ethanol and 28.7 mg sorbitol.
Lupkynis may contain trace amounts of soya lecithin, see section 4.4.
For the full list of excipients, see section 6.1.
Active Ingredient | Description | |
---|---|---|
Voclosporin |
Voclosporin is a calcineurin-inhibitor immunosuppressant that inhibits calcineurin in a dose-dependent manner. The immunosuppressant activity results in inhibition of lymphocyte proliferation, T-cell cytokine production, and expression of T-cell activation surface antigens. |
List of Excipients |
---|
Capsule content: Ethanol Capsule shell: Gelatin Processing aids: Soya lecithin |
Soft capsules are available in cold-formed aluminium blisters, laminated backing and lidding materials that are thermo-sealed together. Each blister contains 18 soft capsules. One carton contains 180 or 576 soft capsules.
Not all pack sizes may be marketed.
Otsuka Pharmaceutical Netherlands B.V., Herikerbergweg 292, 1101 CT Amsterdam, Netherlands
Date of first authorisation: 15 September 2022
Drug | Countries | |
---|---|---|
LUPKYNIS | Austria, Cyprus, Estonia, Spain, Finland, France, Croatia, Ireland, Italy, Lithuania, Romania, United Kingdom, United States |
© All content on this website, including data entry, data processing, decision support tools, "RxReasoner" logo and graphics, is the intellectual property of RxReasoner and is protected by copyright laws. Unauthorized reproduction or distribution of any part of this content without explicit written permission from RxReasoner is strictly prohibited. Any third-party content used on this site is acknowledged and utilized under fair use principles.